CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Novo's CagriSema fails to match Lilly's Zepbound in key obesity trial FirstWord Pharma Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN